Perigon Wealth Management LLC Invests $1 Million in Illumina, Inc. $ILMN

Perigon Wealth Management LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, HoldingsChannel reports. The fund acquired 5,708 shares of the life sciences company’s stock, valued at approximately $1,004,000.

Several other institutional investors have also recently made changes to their positions in ILMN. Elyxium Wealth LLC acquired a new stake in Illumina during the fourth quarter valued at $25,000. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the fourth quarter worth about $26,000. Laurel Wealth Advisors LLC acquired a new position in shares of Illumina in the fourth quarter worth about $26,000. Elevation Wealth Partners LLC raised its position in shares of Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after acquiring an additional 84 shares during the period. Finally, Activest Wealth Management boosted its stake in shares of Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 215 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the transaction, the insider owned 20,338 shares in the company, valued at $4,067,600. The trade was a 2.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,415,351 shares of company stock worth $255,966,311. 2.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ILMN has been the topic of a number of analyst reports. Leerink Partners raised their target price on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Barclays increased their price target on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. Royal Bank Of Canada raised their price objective on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Finally, Canaccord Genuity Group upped their target price on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $188.40.

Illumina Stock Performance

NASDAQ ILMN opened at $188.29 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock’s fifty day moving average is $185.05 and its two-hundred day moving average is $151.10. The firm has a market capitalization of $28.43 billion, a P/E ratio of 35.13, a price-to-earnings-growth ratio of 2.69 and a beta of 1.44. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $207.00.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the company posted $1.19 EPS. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.